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Patients with renal dysfunction  
are slower to have blood pressure 
dips at night
In healthy subjects, blood pressure normally dips at night by 10% 
to 20%. In some patients with hypertension or chronic kidney 
disease (CKD), however, blood pressure fails to dip as much at 
night; these patients have thus been called ‘nondippers.’ Fukuda 
et al. previously reported that patients with essential hyperten-
sion had diminished nighttime dips in blood pressure as their 
blood pressure became sodium sensitive. The authors have pos-
tulated that poor kidney function weakens the kidney’s capacity 
to excrete sodium, thus causing nocturnal blood pressure eleva-
tion. This enhances nighttime natriuresis (excretion of abnor-
mal amounts of sodium in urine) to compensate for impaired 
daytime natriuresis. If such a mechanism holds, high blood pres-
sure during sleep at night may continue until excess sodium is 
sufficiently excreted into the urine. Now, the authors examine 
whether the duration, defined as ‘dipping time,’ until noctur-
nal mean arterial pressure begins to fall to less than 90% of the 
daytime average becomes longer as renal function deteriorates. 
Ambulatory blood pressure measurements and urinary sodium 
excretion rates were evaluated for daytime and nighttime to esti-
mate their circadian rhythms in 65 subjects with CKD. Dipping 
time showed an inverse relationship with creatinine clearance 
and positive relationships with night/day ratios of mean arterial 
pressure and natriuresis, both of which were also inversely cor-
related with creatinine clearance. When divided into tertiles by 
creatinine clearance (ml/min), hazard ratios of nocturnal blood 
pressure dip adjusted for age, sex, and body mass index were 
0.37 (95% confidence interval: 0.17–0.79; P=0.01) for the second 
tertile and 0.20 for the third tertile compared with the first tertile. 
These findings demonstrate that patients with renal dysfunction 
require a longer duration until blood pressure falls during sleep 
at night. Because it is well known that blood pressure during 
sleep has a greater impact on heart disease than blood pressure 
during the day, circadian blood pressure rhythm should be an 
important risk factor for heart disease. Furthermore, dipping 
time may be used as a novel marker to analyze circadian blood 
pressure rhythm, and shortening dipping time could become a 
new target of antihypertensive therapy. (Hypertension advance 
online publication, 20 October 2008; doi:10.1161/HYPERTEN-
SIONAHA.108.115329)
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Combination of angiotensin 1 
blocker and vitamin D analogue 
ameliorates diabetic nephropathy
Several lines of evidence suggest that the renin–angiotensin 
system (RAS) is a major mediator of renal injury in diabetic 
nephropathy, and drugs targeting the RAS have been shown 
to reduce its progression. The systemic components of the 
RAS are actually downregulated in diabetes mellitus, but all 
components of the RAS are present within the kidney, and 
renal interstitial angiotensin II levels are manyfold higher 
than those in plasma. Intrarenal renin and angiotensinogen 
levels are induced in diabetic animals, and high glucose has 
been shown to stimulate renin and angiotensin II synthesis 
in mesangial cells and podocytes. 1,25-Dihydroxyvitamin D3 
(1,25(OH)2D3), the hormonal form of vitamin D, is a negative 
regulator of the RAS, since it suppresses renin transcription; 
mice lacking the vitamin D receptor gene develop hyper-
reninemia, high blood pressure, and cardiac hypertrophy. 
Recent studies also showed that vitamin D receptor-null mice 
developed more severe diabetic nephropathy than wild-type 
mice, suggesting that vitamin D plays a protective role against 
hyperglycemia-induced renal injury, perhaps by regulating the 
RAS. Zhang et al. examined whether vitamin D or vitamin 
D analogues have therapeutic effects in diabetic nephropa-
thy. Streptozotocin-treated diabetic mice developed progres-
sive albuminuria and glomerulosclerosis, accompanied by 
increased intrarenal production of angiotensin II, fibronectin, 
transforming growth factor-β (TGF-β), and monocyte chem-
otactic protein-1 (MCP-1) and decreased expression of slit 
diaphragm proteins. Treatment of the diabetic mice with losa-
rtan or paricalcitol (an activated vitamin D analogue) alone 
moderately ameliorated kidney injury; however, combined 
treatment with losartan and paricalcitol completely prevented 
albuminuria, restored glomerular filtration barrier structure, 
and markedly reduced glomerulosclerosis. The combined 
treatment suppressed the induction of fibronectin, TGF-β, 
and MCP-1 and reversed the decline of the slit diaphragm 
proteins nephrin, Neph-1, ZO-1, and α-actinin-4. These 
changes were accompanied by blockade of intrarenal renin 
and angiotensin II accumulation induced by hyperglycemia 
and losartan (Figure). These data demonstrate that inhibition 
of the RAS with the combination of vitamin D analogues and 
RAS inhibitors effectively prevented renal injury in diabetic 
nephropathy in mice. (Proc Natl Acad Sci USA 2008; 105: 
15896–15901; doi:10.1073/pnas.0803751105)
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Intrarenal angiotensin II and renin. Immunostaining of kidney in 
glomerular (a–e) and tubular (f–j) areas with angiotensin II–specific 
antibody. Nondiabetic control mice (a and f) and diabetic mice treated 
with vehicle (b and g), losartan (c and h), paricalcitol (d and i), or both 
drugs (L+P; e and j).
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Tackling the challenges  
to health equity in China
Economic reforms in China during the past three decades 
have sparked unprecedented economic growth and have led to 
large reductions in income poverty. During this time, however, 
China’s health care services have been slipping, particularly 
in rural areas. While the Chinese government increasingly 
recognizes these challenges and is responding to them, the 
country’s daunting health equity challenges remain. They have 
resulted from the three following synergistic factors: inequita-
ble social determinants of health (as demonstrated by higher 
child malnutrition in rural areas and less access to clean water 
and sanitation in rural areas); imbalances in the roles of the 
market and government; and growing concerns among the 
public about fairness in health. With its economic boom and 
growing government revenues, China is unlike other countries 
challenged by health inequities in that it can afford the neces-
sary reforms needed to improve health equity. A new article by 
Tang et al. discusses these challenges and the proposed reforms, 
which should receive immense popular support, governmental 
commitment, and interest from the public health community 
worldwide. (Lancet 2008; 372: 1493–1501)
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Hydrogen sulfide deficiency 
causes hypertension
During the past two decades, many studies have established 
the fundamental importance of gaseous signaling molecules 
such as nitric oxide (NO) and carbon monoxide (CO) in biol-
ogy and medicine. Recent work has suggested that another 
endogenous gas, hydrogen sulfide (H2S), may also be a physi-
ological messenger molecule. H2S synthesis from cysteine has 
been shown in a variety of mammalian tissues, principally by 
the activity of two enzymes, cystathionine γ-lyase (CSE) and 
cystathionine β-synthetase, but it is unclear whether these 
enzymes generate H2S in vivo. Nonetheless, micromolar 
concentrations of H2S have been detected in rat and human 
blood as well as in homogenates of several tissues, including 
the kidney. H2S causes dose-dependent relaxation in isolated 
arteries (most likely by an effect on vascular smooth muscle 
KATP channels) and reduces blood pressure in the anesthe-
tized animals, but whether H2S plays a role in the normal con-
trol of cardiovascular function is not yet known. In a recent 
study, Yang et al. demonstrated that under physiological con-
ditions, H2S was generated by CSE. Genetic deletion of this 
enzyme in mice (CSE–/–) markedly reduced H2S levels in the 
serum, heart, aorta, and other tissues. Of great interest, CSE–/– 
mice displayed pronounced hypertension and diminished 
endothelium-dependent vasorelaxation. Direct stimulation 
of the vascular smooth muscle of arteries from CSE–/– mice 
was found to be unaffected, but methacholine-induced relaxa-
tion of mesenteric arteries that had been constricted by phe-
nylephrine was markedly impaired in mutant mice. Further, 
endothelial removal abolished relaxation induced by cholin-
ergic stimulation of both wild-type and mutant mice arter-
ies. Immunohistochemistry analysis showed that CSE protein 
predominantly localized to the endothelium, with faint stain-
ing in smooth muscle (Figure). Thus, H2S displays properties 
characteristic of an endothelium-derived relaxing factor: its 
formation takes place in endothelium, and prevention of its 
synthesis impairs relaxation elicited by a neurotransmitter 
that acts via the endothelium. The relative extent to which 
H2S, NO, or CO contributes to endothelial-derived relax-
ing action in different vascular beds remains to be clarified. 
(Science 2008; 322: 587–590; doi:10.1126/science.1162667)
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Immunohistochemical localization of cystathionine γ-lyase (CSE) to 
arterial endothelium is abolished in CSE–/– mice.
